289 related articles for article (PubMed ID: 37660335)
1. Systemic Treatment for Cholangiocarcinoma.
Sookprasert A; Wirasorn K; Chindaprasirt J; Watcharenwong P; Sanlung T; Putraveephong S
Recent Results Cancer Res; 2023; 219():223-244. PubMed ID: 37660335
[TBL] [Abstract][Full Text] [Related]
2. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
[TBL] [Abstract][Full Text] [Related]
3. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
4. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
Lodl E; Ramnaraign B; Sahin I; Wheeler S
J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
[TBL] [Abstract][Full Text] [Related]
5. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
Merath K; Tiwari A; Parikh AA; Pawlik TM
Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
[TBL] [Abstract][Full Text] [Related]
7. [Current Studies and Evidence in Cholangiocarcinoma].
Zimpel C; Mitzlaff K; Jasper NA; Marquardt JU
Zentralbl Chir; 2022 Aug; 147(4):389-397. PubMed ID: 35863357
[TBL] [Abstract][Full Text] [Related]
8. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
9. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
Uson Junior PLS; Bearss J; Babiker HM; Borad MJ
Expert Opin Investig Drugs; 2023 Jan; 32(1):69-75. PubMed ID: 36714945
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
11. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
Du J; Lv X; Zhang Z; Huang Z; Zhang E
Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
[TBL] [Abstract][Full Text] [Related]
12. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Ang C
J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
[TBL] [Abstract][Full Text] [Related]
13. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
Chakrabarti S; Finnes HD; Mahipal A
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
[TBL] [Abstract][Full Text] [Related]
16. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract][Full Text] [Related]
17. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
[No Abstract] [Full Text] [Related]
19. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]